participants with any of the following criteria will be excluded: history of laboratory-confirmed sars-cov-2 infection. history of seizures, encephalopathy, or psychosis. known or suspected allergy or history of anaphylaxis or other serious adverse reactions to any vaccine or study vaccine and/or any other excipients of the vaccine. pregnant, breastfeeding or planning to become pregnant within 6 months after the study vaccine administration. suspected active infection or other acute illness, including fever > 37.2°c. any presence of clinical relevance of cardiovascular disease (including but not limited to arrythmia, myocardial infarction, uncontrolled hypertension, coronary artery disease, or congestive heart failure). any presence of clinical relevance of serious chronic disease [asthma, diabetes, thyroid diseases etc.). any presence of clinical relevance of congenital or acquired angioedema. diagnosis of immunodeficiency. diagnosis of bleeding diathesis. use of immunosuppressive medications, anti-allergic therapy, cytotoxic therapy, inhaler corticosteroids (excluding allergic rhinitis or topical steroid ointments). those who received blood/plasma products or immunoglobulins and/or blood transfusion within the last 6 months. those who participated in another vaccine study or received an investigational/experimental drug within 1 month prior to study entry. history of any live vaccine within 1 month prior to study participation. history of any inactivated vaccine within 1 month prior to study participation. use of active tuberculosis treatment. according to the investigator's judgement, those who have any condition (medical, psychological, social, etc.) that may impair the subject's compliance with the study

participants with any of the following criteria will be excluded: history of laboratory-confirmed sars-cov-2 infection. history of seizures, encephalopathy, or psychosis. known or suspected allergy or history of anaphylaxis or other serious adverse reactions to any vaccine or study vaccine and/or any other excipients of the vaccine. pregnant, breastfeeding or planning to become pregnant within 6 months after the study vaccine administration. suspected active infection or other acute illness, including fever > 37.2°c. any presence of clinical relevance of cardiovascular disease (including but not limited to arrythmia, myocardial infarction, uncontrolled hypertension, coronary artery disease, or congestive heart failure). any presence of clinical relevance of serious chronic disease [asthma, diabetes, thyroid diseases etc.). any presence of clinical relevance of congenital or acquired angioedema. diagnosis of immunodeficiency. diagnosis of bleeding diathesis. use of immunosuppressive medications, anti-allergic therapy, cytotoxic therapy, inhaler corticosteroids (excluding allergic rhinitis or topical steroid ointments). those who received blood/plasma products or immunoglobulins and/or blood transfusion within the last 6 months. those who participated in another vaccine study or received an investigational/experimental drug within 1 month prior to study entry. history of any live vaccine within 1 month prior to study participation. history of any inactivated vaccine within 1 month prior to study participation. use of active tuberculosis treatment. according to the investigator's judgement, those who have any condition (medical, psychological, social, etc.) that may impair the subject's compliance with the study

participants with any of the following criteria will be excluded: 1. history of laboratory-confirmed sars-cov-2 infection. 2. history of seizures, encephalopathy, or psychosis. 3. known or suspected allergy or history of anaphylaxis or other serious adverse reactions to any vaccine or study vaccine and/or any other excipients of the vaccine. 4. pregnant, breastfeeding or planning to become pregnant within 6 months after the study vaccine administration. 5. suspected active infection or other acute illness, including fever > 37.2°c. 6. any presence of clinical relevance of cardiovascular disease (including but not limited to arrythmia, myocardial infarction, uncontrolled hypertension, coronary artery disease, or congestive heart failure). 7. any presence of clinical relevance of serious chronic disease [asthma, diabetes, thyroid diseases etc.). 8. any presence of clinical relevance of congenital or acquired angioedema. 9. diagnosis of immunodeficiency. 10. diagnosis of bleeding diathesis. 11. use of immunosuppressive medications, anti-allergic therapy, cytotoxic therapy, inhaler corticosteroids (excluding allergic rhinitis or topical steroid ointments). 12. those who received blood/plasma products or immunoglobulins and/or blood transfusion within the last 6 months. 13. those who participated in another vaccine study or received an investigational/experimental drug within 1 month prior to study entry. 14. history of any live vaccine within 1 month prior to study participation. 15. history of any inactivated vaccine within 1 month prior to study participation. 16. use of active tuberculosis treatment. 17. according to the investigator's judgement, those who have any condition (medical, psychological, social, etc.) that may impair the subject's compliance with the study

participants with any of the following criteria will be excluded: 1. history of laboratory-confirmed sars-cov-2 infection. 2. history of seizures, encephalopathy, or psychosis. 3. known or suspected allergy or history of anaphylaxis or other serious adverse reactions to any vaccine or study vaccine and/or any other excipients of the vaccine. 4. pregnant, breastfeeding or planning to become pregnant within 6 months after the study vaccine administration. 5. suspected active infection or other acute illness, including fever > 37.2°c. 6. any presence of clinical relevance of cardiovascular disease (including but not limited to arrythmia, myocardial infarction, uncontrolled hypertension, coronary artery disease, or congestive heart failure). 7. any presence of clinical relevance of serious chronic disease [asthma, diabetes, thyroid diseases etc.). 8. any presence of clinical relevance of congenital or acquired angioedema. 9. diagnosis of immunodeficiency. 10. diagnosis of bleeding diathesis. 11. use of immunosuppressive medications, anti-allergic therapy, cytotoxic therapy, inhaler corticosteroids (excluding allergic rhinitis or topical steroid ointments). 12. those who received blood/plasma products or immunoglobulins and/or blood transfusion within the last 6 months. 13. those who participated in another vaccine study or received an investigational/experimental drug within 1 month prior to study entry. 14. history of any live vaccine within 1 month prior to study participation. 15. history of any inactivated vaccine within 1 month prior to study participation. 16. use of active tuberculosis treatment. 17. according to the investigator's judgement, those who have any condition (medical, psychological, social, etc.) that may impair the subject's compliance with the study